Clinical Cancer Research, Vol 3, Issue 11 1943-1948, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors

Z Fan, BY Shang, Y Lu, JL Chou and J Mendelsohn
The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

Many human epithelial tumors express high levels of epidermal growth factor (EGF) receptors. A human-mouse chimeric version of anti-EGF receptor monoclonal antibody (mAb) C225, which blocks receptor activation and produces inhibition of cell proliferation, is currently being investigated in clinical trials. When cells bear high numbers of EGF receptors, either complete blockade of receptors with mAb 225 or full activation of receptors with EGF results in inhibition of proliferation. In the present study, we have explored the molecular mechanisms explaining how a receptor inhibitor, mAb 225, and a receptor activator, EGF, can both produce growth inhibition of A431 human squamous epithelial carcinoma cells. We reported previously that inhibition of A431 cells by EGF is associated with up-regulation of p21(Cip1). We now demonstrate that mAb 255-mediated inhibition is associated with up-regulation of p27(Kip1), which binds to and inactivates cyclin-dependent kinase-2 activity and produces cell cycle arrest in G1. Furthermore, inhibition by mAb 225 can be overcome by titrating the cultures with increasing concentrations of EGF, which is accompanied by a concurrent fall in the level of p27(Kip1). At properly titrated concentrations of mAb 225 and EGF, the inhibitory activities of both mAb 225 and EGF are counterbalanced and abolished. When EGF concentrations reach levels high enough to compete with mAb to produce near-saturating levels of receptor activation, p27(Kip1) falls below basal levels; however, the concomitant marked rise in the level of p21(Cip1) results in growth inhibition. Our data suggest that although p27(Kip1) and p21(Cip1) are induced and act independently, they play reciprocal roles in mediating inhibition of A431 cell growth by blockade of EGF receptors with mAb 225 and by activation of receptors with saturating concentrations of EGF.

This article has been cited by other articles:

				R. L. Mahtani and J. S. Macdonald Synergy Between Cetuximab and Chemotherapy in Tumors of the Gastrointestinal Tract Oncologist, January 1, 2008; 13(1): 39 - 50. [Abstract] [Full Text] [PDF]

				A. Bozec, P. Formento, J. Ciccolini, R. Fanciullino, L. Padovani, X. Murraciole, J.-L. Fischel, and G. Milano Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation Mol. Cancer Ther., December 1, 2005; 4(12): 1962 - 1971. [Abstract] [Full Text] [PDF]

				R. M. Perera, Y. Narita, F. B. Furnari, H. K. Gan, C. Murone, M. Ahlkvist, R. B. Luwor, A. W. Burgess, E. Stockert, A. A. Jungbluth, et al. Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor-Specific Antibody Generates Enhanced Antitumor Activity Clin. Cancer Res., September 1, 2005; 11(17): 6390 - 6399. [Abstract] [Full Text] [PDF]

				L A Bazley and W J Gullick The epidermal growth factor receptor family Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S17 - S27. [Abstract] [Full Text] [PDF]

				S. K. Mohsin, H. L. Weiss, M. C. Gutierrez, G. C. Chamness, R. Schiff, M. P. DiGiovanna, C.-X. Wang, S. G. Hilsenbeck, C. K. Osborne, D. C. Allred, et al. Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers J. Clin. Oncol., April 10, 2005; 23(11): 2460 - 2468. [Abstract] [Full Text] [PDF]

				P M Harari Epidermal growth factor receptor inhibition strategies in oncology Endocr. Relat. Cancer, December 1, 2004; 11(4): 689 - 708. [Abstract] [Full Text] [PDF]

				M Theodoropoulou, T Arzberger, Y Gruebler, M L Jaffrain-Rea, J Schlegel, L Schaaf, E Petrangeli, M Losa, G K Stalla, and U Pagotto Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells J. Endocrinol., November 1, 2004; 183(2): 385 - 394. [Abstract] [Full Text] [PDF]

				L. Castillo, M. C. Etienne-Grimaldi, J. L. Fischel, P. Formento, N. Magne, and G. Milano Pharmacological background of EGFR targeting Ann. Onc., July 1, 2004; 15(7): 1007 - 1012. [Abstract] [Full Text] [PDF]

				J-L Yang, X-J Qu, P J Russell, and D Goldstein Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon {alpha} Gut, January 1, 2004; 53(1): 123 - 129. [Abstract] [Full Text] [PDF]

				L. Lo Muzio, G. Pannone, R. Leonardi, S. Staibano, M.D. Mignogna, G. De Rosa, Y. Kudo, T. Takata, and D.C. Altieri Survivin, a Potential Early Predictor of Tumor Progression in the Oral Mucosa J. Dent. Res., November 1, 2003; 82(11): 923 - 928. [Abstract] [Full Text] [PDF]

				T. Karashima, P. Sweeney, J. W. Slaton, S. J. Kim, D. Kedar, J. I. Izawa, Z. Fan, C. Pettaway, D. J. Hicklin, T. Shuin, et al. Inhibition of Angiogenesis by the Antiepidermal Growth Factor Receptor Antibody ImClone C225 in Androgen-independent Prostate Cancer Growing Orthotopically in Nude Mice Clin. Cancer Res., May 1, 2002; 8(5): 1253 - 1264. [Abstract] [Full Text] [PDF]

				A. Viloria-Petit, T. Crombet, S. Jothy, D. Hicklin, P. Bohlen, J. M. Schlaeppi, J. Rak, and R. S. Kerbel Acquired Resistance to the Antitumor Effect of Epidermal Growth Factor Receptor-blocking Antibodies in Vivo: A Role for Altered Tumor Angiogenesis Cancer Res., July 1, 2001; 61(13): 5090 - 5101. [Abstract] [Full Text] [PDF]

				G. Lammering, T. H. Hewit, W. T. Hawkins, J. N. Contessa, D. B. Reardon, P.-S. Lin, K. Valerie, P. Dent, R. B. Mikkelsen, and R. K. Schmidt-Ullrich Epidermal Growth Factor Receptor as a Genetic Therapy Target for Carcinoma Cell Radiosensitization J Natl Cancer Inst, June 20, 2001; 93(12): 921 - 929. [Abstract] [Full Text] [PDF]

				F. R. Khuri and J. M. Kurie Antisense Approaches Enter the Clinic Clin. Cancer Res., May 1, 2000; 6(5): 1607 - 1610. [Full Text]

				C. J. Bruns, M. T. Harbison, D. W. Davis, C. A. Portera, R. Tsan, D. J. McConkey, D. B. Evans, J. L. Abbruzzese, D. J. Hicklin, and R. Radinsky Epidermal Growth Factor Receptor Blockade with C225 Plus Gemcitabine Results in Regression of Human Pancreatic Carcinoma Growing Orthotopically in Nude Mice by Antiangiogenic Mechanisms Clin. Cancer Res., May 1, 2000; 6(5): 1936 - 1948. [Abstract] [Full Text]

				A. D. Perera, E. V. Kleymenova, and C. L. Walker Requirement for the von Hippel-Lindau Tumor Suppressor Gene for Functional Epidermal Growth Factor Receptor Blockade by Monoclonal Antibody C225 in Renal Cell Carcinoma Clin. Cancer Res., April 1, 2000; 6(4): 1518 - 1523. [Abstract] [Full Text]

				D. Busse, R. S. Doughty, T. T. Ramsey, W. E. Russell, J. O. Price, W. M. Flanagan, L. K. Shawver, and C. L. Arteaga Reversible G1 Arrest Induced by Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase Requires Up-regulation of p27KIP1 Independent of MAPK Activity J. Biol. Chem., March 15, 2000; 275(10): 6987 - 6995. [Abstract] [Full Text] [PDF]

				J. Mendelsohn Blockade of Receptors for Growth Factors: An Anticancer Therapy -- The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture Clin. Cancer Res., March 1, 2000; 6(3): 747 - 753. [Full Text]

				J. Baselga, D. Pfister, M. R. Cooper, R. Cohen, B. Burtness, M. Bos, G. D’Andrea, A. Seidman, L. Norton, K. Gunnett, et al. Phase I Studies of Anti-Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin J. Clin. Oncol., February 14, 2000; 18(4): 904 - 904. [Abstract] [Full Text] [PDF]

				N.-h. Guo, N. S. Templeton, H. Al-Barazi, J. Cashel, J. M. Sipes, H. C. Krutzsch, and D. D. Roberts Thrombospondin-1 Promotes {{alpha}}3{beta}1 Integrin-mediated Adhesion and Neurite-like Outgrowth and Inhibits Proliferation of Small Cell Lung Carcinoma Cells Cancer Res., January 1, 2000; 60(2): 457 - 466. [Abstract] [Full Text]

				I. Osman, M. Drobnjak, M. Fazzari, J. Ferrara, H. I. Scher, and C. Cordon-Cardo Inactivation of the p53 Pathway in Prostate Cancer: Impact on Tumor Progression Clin. Cancer Res., August 1, 1999; 5(8): 2082 - 2088. [Abstract] [Full Text] [PDF]

				M. R. Posner, L. A. Cavacini, M. P. Upton, K. C. Tillman, E. R. Gornstein, and C. M. Norris Jr. Surface Membrane-expressed CD40 Is Present on Tumor Cells from Squamous Cell Cancer of the Head and Neck in Vitro and in Vivo and Regulates Cell Growth in Tumor Cell Lines Clin. Cancer Res., August 1, 1999; 5(8): 2261 - 2270. [Abstract] [Full Text] [PDF]